Executive Team

Pat Altavilla

PAT ALTAVILLA
CHIEF EXECUTIVE OFFICER

Pat Altavilla joined Suneva Medical in October 2016 as Vice President of Sales and Marketing after a distinguished 30-year career in the aesthetics and medical fields. Early in her career Altavilla served as vice president of international sales and worldwide marketing for Mentor Corpora­tion, where for nearly 20 years she helped the company grow sales tenfold, launch new prod­ucts, and enhance its global market presence and sales training. Altavilla then worked as vice president of sales, marketing and operations officer at The Plastic Surgery Company, and co-founded and ran Spa Medicu/Medicus Skin Enhancement for several years, before returning to a corporate executive position with BioForm Medical. Altavilla served most notably as vice president of global marketing where she was instrumental in restructuring marketing, growing sales, creating a practice development program and raising the company’s overall visibility in the marketplace. Most recently, Altavilla worked for medical technology company ZELTIQ® Aesthetics Inc. where she served in numerous leadership roles. Altavilla was instrumental in developing the brand’s global marketing organization as well as growing physician loyalty, enhancing practice development, launching innovative products, and increasing the company’s presence.

Dr. Brian K. Pilcher
Chief Scientific Officer

Dr. Brian K. Pilcher brings over 18 years of experience in Dermatology and Aesthetics, most recently as Principal of Critical MASS Scientific Strategy Consultants, where he worked with a number of pharmaceutical and medical device companies to develop programs in support of both established product life cycle and new product launches, as well as medical affairs and clinical education activities. Dr. Pilcher has also served as Vice President of Medical Affairs for Merz North America, Vice President of Medical Affairs and Clinical Education for BioForm Medical, and Director of Research and Development for Cutanix Corporation. In each of these roles, Dr. Pilcher has leveraged his unique combination of scientific and commercial expertise to direct and implement innovative and effective communications platforms and lead medical affairs teams in developing strong relationships with both physician thought leaders and the broader medical community. He has also developed and implemented novel educational initiatives to ensure safe & effective uses of drugs and medical devices, leading a team of 40 nurse and physician assistant educators whose goal is to ensure optimal clinical results while focusing on the highest standards of patient safety and satisfaction. Prior to entering industry, Dr. Picher earned his PhD in Cell and Molecular Biology from the University of Oklahoma College of Medicine, completed post graduate training in Dermatology at Washington University in St. Loius, and was an Assistant Professor at University of Texas Southwestern Medical Center in the Department of Cell Biology where his research focus was on the cellular and molecular mechanisms of wound repair.

Dr. Brian K. Pilcher
Brad Webre

Brad Webre
Vice President of Finance

Brad Webre joined Suneva in February 2016 and serves as our Vice President of Finance with responsibility for leading the company’s finance, accounting and information technology functions. Before joining Suneva, Brad held several senior leadership positions in the consumer products and life sciences industries, most recently as chief financial officer for NEHP, Inc. He brings strategic, operational and transactional experience gained in over 20 years as a senior financial executive including more than $50mm in capital transactions including debt & equity raises and asset acquisition & divestitures. A certified public accountant, Mr. Webre received his bachelor’s degree in economics with an accounting concentration from the University of California, Santa Barbara.

Bob Ingersoll
Vice President of Sales

Bob Ingersoll was appointed to lead Suneva Medical’s US Sales organization in 2019. Mr. Ingersoll has nearly 30 years of success in building and leading sales organizations, with 24 of those years being in the dermatology and aesthetic market place. Mr. Ingersoll has a tremendous track record of launching new products into the market place while building great customer satisfaction and loyalty. His most recent experience was the turnaround of Envy Medical Inc. During his tenure at Envy Medical, he led the organization to a 200% increase in revenue in just 2 years. This rapid sales growth and increase in market awareness directly led to Envy Medical’s acquisition by Allergan.

During his career, he has had success at Envy Medical, Johnson and Johnson, Medicis Pharmaceuticals, Onset Dermatologics and Encore Dermatology. In addition to his successful career in health care, Mr. Ingersoll proudly served as an Officer in United States Army.

He earned a BA degree from the University of Southern California and an MBA from Pepperdine University.

Bob Ingersoll
Andy Vutam

Andy Vutam
VP of Marketing and International Business Development

Andy Vutam joined Suneva Medical, Inc. in 2017. He has over 15 years of experience marketing consumer healthcare and lifestyle brands for major global companies like Johnson and Johnson and small start-ups. Andy’s first role in the aesthetics industry was with BioForm Medical, Inc. that was later acquired by Merz Aesthetics. While at Merz Aesthetics, he became the Global Marketing Director for RADIESSE and BELOTERO dermal filler. He also led the digital marketing efforts for the entire aesthetic portfolio. Andy later took a role with ZELTIQ Aesthetics, Inc. as the Director of International Marketing where he led the launch and expansion of CoolSculpting into the EMEA, APAC and LATAM regions. Today he is the VP of Marketing and International Business Development for Suneva Medical, Inc. He holds a bachelor’s degree in English Literature from The George Washington University in Washington, D.C.

Pam Misajon
Vice President of Regulatory, Quality Affairs and Compliance

Pam Misajon joined Suneva in February 2017 and serves as our Vice President of Regulatory, Quality Affairs and Compliance. Ms. Misajon has over 25 years’ experience in both established and start-up medical device companies’ in the areas of regulatory, quality and clinical affairs. Her experience includes gaining U.S. and worldwide product approvals, developing compliant quality systems, and overseeing the execution of clinical studies. Prior to joining Suneva Medical, Ms. Misajon was Vice President of Regulatory Affairs for Neomend, Inc. (acquired by CR BARD in 2012) which specialized in Class III surgical sealants. Ms. Misajon has held executive positions with Ellipse Technologies, Pegasus Biologics, and Intraluminal Therapeutics.

Pam Misajon

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.